Potential negative effects of the free use of chloroquine to manage COVID-19 in Colombia.

INTRODUCTION

Coronavirus disease 2019 (COVID‐19) pandemic has challenged healthcare systems around the world. Unfortunately, failure has become evident with the collapse of high‐income countries where excellent‐quality and efficient systems—with enough resources and advanced scientific technology to establish strong public health strategies based on mathematical models adjusted to serve COVID‐19 —have undergone significant strain.

Currently, there are no effective pharmacological interventions with sufficient scientific evidence to treat COVID‐19. Fueled by the epidemiological and clinical impact of its rapid spread, and the alarming fatality rates of over 10% in some countries, the need for in‐hospital management—especially in intensive care units (ICU)—geared public health attention towards previous pharmacological experiences evaluated in other coronavirus strains. , ,

CHLOROQUINE AND COVID‐19

Chloroquine phosphate (CQ) stood out among potential personalized pharmacological therapies for COVID‐19 due to the antiviral effect demonstrated in preclinical studies and its high specificity towards the SARS‐CoV‐2 receptor: angiotensin‐converting enzyme 2 (ACE‐2). High distribution within lung tissue (the main organ affected in COVID‐19),  and the results described in case series of critically ill COVID‐19 patients with favorable clinical outcomes after being treated with CQ have suggested its possible use as a suitable pharmacological option. , Based on published evidence, Colombia, China, India, United States, and other countries have included CQ within the management guidelines for COVID‐19 or as an extreme measure in patients with a high risk of death. However, its effectiveness against COVID‐19 has recently been questioned, and studies suggest that CQ should be used with caution in the treatment of severe presentations of disease based on its potential cardiotoxic side effects and increased lethality.

In response to this initiative, the World Health Organization issued a warning on how the use of unproven drugs could generate shortages to treat other diseases for which efficacy has already been proven, referring to chloroquine, commonly used to treat malaria and autoimmune disorders.

CHLOROQUINE REPURPOSING AND RHEUMATIC AUTOIMMUNE DISEASE IN COLOMBIA

Recently, the Colombian government established that "after finding scientific evidence, the use of chloroquine and hydroxychloroquine is considered given the possibility that medical personnel may consider its use for the treatment of COVID‐19". However, this would be an off‐label indication given that the effectiveness of chloroquine in treating patients with COVID‐19 is supported mainly by in‐vitro studies, animal models, anecdotic evidence and by ongoing clinical trials without definitive results. Another problem is the limited sample size of many of these trials, and the possible selection bias towards critically ill patients with pneumonia. , , Chloroquine and hydroxychloroquine are first‐line medications to treat systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and Sjögren syndrome (SS). They are also indicated in primary antiphospholipid syndrome, erythema nodosum associated with autoimmunity, septal panniculitis of autoimmune etiology, sarcoidosis, among other rheumatic autoimmune diseases (RADs). According to data from the Comprehensive Social Protection Information System, the number of patients diagnosed in Colombia with SLE, RA, or SS increased by 78.8% between 2015 and 2019 (Figure 1A,B).

Figure 1

Frequency of patients with neglected autoimmune and infectious diseases susceptible to Chloroquine shortages in Colombia. A, Annual frequency of patients diagnosed with autoimmune rheumatic diseases (ARDs). B, Annual medical visits to patients with Rheumatoid arthritis, Systemic lupus erythematosus or Sjogren's syndrome. C, Annual frequency of diagnosed cases of malaria

MALARIA IN COLOMBIA AND THE REGION

Data from the Colombian Public Health Surveillance System showed a 47.4% increase in confirmed malaria cases between 2015 and 2019; the increase in P. vivax and P. falciparum malaria cases was 56.1% and 45.4%, respectively  (Figure 1C) with an annual parasite index of 4.98 cases for every 1000 inhabitants in 2019. Based on annual projections, and anticipating the wide use of CQ during the mitigation phase of COVID‐19, the Ministry of Health and Social Protection established that necessary provisions of this drug should be reserved so as not to deprive susceptible population from malaria treatment. Colombia is one of the countries with the highest reports of malaria in the region (117 650) , and indeed requires a large stash of this drug. Including CQ as a drug‐of‐choice for COVID‐19 could result in a drastic reduction in malaria treatment availability in the country. Taking this into account, recommending an off‐label medication to healthcare personnel that lacks approval, regulation, and evidence of efficacy against COVID‐19 pneumonia could generate misinformation among the general population, promoting massive panic‐buying behaviors and creating an over‐cost and shortage problem that may lead to a serious public health issue.

On the other hand, a "kill two birds with one stone" approach would be favorable in particular epidemiological settings such as COVID‐19 and malaria overlapping areas. This is the case of the Colombian Amazon department—the 7th most affected by COVID‐19 and one of the five Colombian departments without ICU services —where long‐time prevalent malaria and the abrupt increase in COVID‐19 cases have started to overlap. Capitalizing on the use of CQ to treat both conditions could result in advantageous and is definitely a topic that deserves further investigation.

CURRENT STATUS OF CHLOROQUINE AND FINAL CONSIDERATIONS

As of 25th April 2020, there are 23 clinical trials registered for the management of COVID‐19 using chloroquine in "recruiting" (n: 11), "not yet recruiting" (n: 10) and "enrolling by invitation" (n: 2) phases, and to date, the two most rigorous clinical trials published with partial or complete results have not shown favorability, with one of them having to be suspended 6 days after beginning due to elevated rates of adverse cardiac effects. , In addition to the nonsupporting evidence on the use of chloroquine to manage COVID‐19, the impact of medicine shortages in patients with RADs could translate into an increased risk of relapses and exacerbations; and in the case of SLE, patients could be at risk for intensive care requirement or even death. The same stands for malaria, where Latin‐American countries such as Colombia, Venezuela, and Brazil report the highest prevalence rates of Plasmodium infection and where prompt treatment must be put in place to reduce disease burden. , Reconsideration from the Colombian national government on the final decision of choosing chloroquine as a first‐line treatment for the management of COVID‐19 should be encouraged.

CONFLICT OF INTERESTS

The authors declare that there are no conflict of interests.